Natera (NASDAQ:NTRA) CFO Sells $573,232.28 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,413 shares of the business’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $237.56, for a total value of $573,232.28. Following the completion of the sale, the chief financial officer owned 60,926 shares of the company’s stock, valued at approximately $14,473,580.56. This trade represents a 3.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $230.40, for a total value of $430,156.80.
• On Tuesday, January 27th, Michael Burkes Brophy sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $188,575.52.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The shares were sold at an average price of $242.54, for a total value of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,621,553.52.

Natera Stock Down 0.1%

NTRA stock opened at $231.14 on Friday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The business has a 50-day simple moving average of $235.91 and a 200 day simple moving average of $194.11. The company has a market cap of $31.97 billion, a PE ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.26) earnings per share. On average, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Barclays lifted their target price on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Evercore ISI raised their price target on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, Piper Sandler lifted their price target on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Hedge Funds Weigh In On Natera

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after purchasing an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after buying an additional 1,003,129 shares during the last quarter. State Street Corp increased its stake in shares of Natera by 2.2% in the third quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after buying an additional 72,087 shares during the period. Franklin Resources Inc. raised its position in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after acquiring an additional 727,366 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Natera by 7.0% in the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after acquiring an additional 166,768 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.